Published in Expert Rev Cardiovasc Ther on November 01, 2010
17β-Estradiol attenuates hypoxic pulmonary hypertension via estrogen receptor-mediated effects. Am J Respir Crit Care Med (2012) 1.95
Sex and menopause differences in response to tadalafil: 6-minute walk distance and time to clinical worsening. Pulm Circ (2015) 0.79
Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med (1991) 13.21
Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol (2009) 12.05
Bosentan therapy for pulmonary arterial hypertension. N Engl J Med (2002) 11.18
Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med (2005) 9.27
Estrogen carcinogenesis in breast cancer. N Engl J Med (2006) 8.17
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med (1996) 8.02
Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet (2000) 7.20
Treatment of pulmonary arterial hypertension. N Engl J Med (2004) 6.88
Primary pulmonary hypertension. A national prospective study. Ann Intern Med (1987) 6.80
Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J (2009) 6.64
Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med (2006) 6.06
Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol (2009) 5.31
Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med (1993) 4.91
An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med (1992) 4.74
Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation (2010) 4.66
Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation (2002) 4.42
Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest (2009) 4.08
Inhaled iloprost for severe pulmonary hypertension. N Engl J Med (2002) 3.90
Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis (1998) 3.48
Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med (2008) 3.13
Tadalafil therapy for pulmonary arterial hypertension. Circulation (2009) 2.98
Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation (2005) 2.98
Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J (2010) 2.90
Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. J Am Coll Cardiol (1998) 2.90
Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet (2000) 2.82
Association of the metabolic syndrome with pulmonary venous hypertension. Chest (2009) 2.75
An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J Clin Invest (2008) 2.71
Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle. Circ Res (2004) 2.69
Clinical risk factors for portopulmonary hypertension. Hepatology (2008) 2.62
Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. Circulation (2007) 2.60
Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol (2009) 2.57
BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet (2000) 2.51
Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest (2010) 2.35
Normal reference values for the adult right ventricle by magnetic resonance imaging. Am J Cardiol (2006) 2.13
Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum (2006) 2.04
Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension. Am J Physiol Heart Circ Physiol (2010) 2.03
Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension? Eur Heart J (2009) 1.93
Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology (2000) 1.86
Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol (2005) 1.82
Insulin resistance in pulmonary arterial hypertension. Eur Respir J (2008) 1.80
Dehydroepiandrosterone upregulates soluble guanylate cyclase and inhibits hypoxic pulmonary hypertension. Cardiovasc Res (2007) 1.70
Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females. Eur Respir J (2009) 1.68
Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum (2007) 1.67
Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension. Am J Respir Crit Care Med (1995) 1.60
Penetrance of pulmonary arterial hypertension is modulated by the expression of normal BMPR2 allele. Hum Mutat (2009) 1.60
Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene. Circulation (2007) 1.53
Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32. Nat Genet (1997) 1.52
Age and sex influence on pulmonary hypertension of chronic hypoxia and on recovery. Am J Physiol (1981) 1.51
Rac and Rho play opposing roles in the regulation of hypoxia/reoxygenation-induced permeability changes in pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol (2004) 1.48
Mice expressing BMPR2R899X transgene in smooth muscle develop pulmonary vascular lesions. Am J Physiol Lung Cell Mol Physiol (2008) 1.47
Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med (2009) 1.44
Relationship of BMPR2 mutations to vasoreactivity in pulmonary arterial hypertension. Circulation (2006) 1.37
Gene expression in BMPR2 mutation carriers with and without evidence of pulmonary arterial hypertension suggests pathways relevant to disease penetrance. BMC Med Genomics (2008) 1.37
CYP1A1 and CYP1B1 polymorphisms and risk of lung cancer among never smokers: a population-based study. Carcinogenesis (2005) 1.28
BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease. Eur Respir J (2004) 1.28
Gender differences in the vasomotor effects of different steroid hormones in rat pulmonary and coronary arteries. Horm Metab Res (2001) 1.28
Rac1 and RhoA as regulators of endothelial phenotype and barrier function in hypoxia-induced neonatal pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol (2006) 1.27
Determinants of right ventricular ejection fraction in pulmonary arterial hypertension. Chest (2008) 1.27
Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review. Eur Respir J (2006) 1.23
Endogenous estrogen attenuates pulmonary artery vasoreactivity and acute hypoxic pulmonary vasoconstriction: the effects of sex and menstrual cycle. Am J Physiol Endocrinol Metab (2007) 1.19
BMP2 induction of actin cytoskeleton reorganization and cell migration requires PI3-kinase and Cdc42 activity. J Cell Sci (2008) 1.18
2-Methoxyestradiol mediates the protective effects of estradiol in monocrotaline-induced pulmonary hypertension. Vascul Pharmacol (2006) 1.17
The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest (1997) 1.17
Pulmonary vasodilatory action of testosterone: evidence of a calcium antagonistic action. J Cardiovasc Pharmacol (2002) 1.17
Cytochrome P450 interactions in human cancers: new aspects considering CYP1B1. Expert Opin Drug Metab Toxicol (2005) 1.16
Expression of cytochromes P450 1A1 and 1B1 in human lung from smokers, non-smokers, and ex-smokers. Toxicol Appl Pharmacol (2004) 1.16
Estradiol-induced attenuation of pulmonary hypertension is not associated with altered eNOS expression. Am J Physiol Lung Cell Mol Physiol (2001) 1.13
Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J Am Coll Cardiol (2006) 1.11
Involvement of RhoA/Rho kinase signaling in protection against monocrotaline-induced pulmonary hypertension in pneumonectomized rats by dehydroepiandrosterone. Am J Physiol Lung Cell Mol Physiol (2008) 1.10
Polymorphisms in genes involved in sex hormone metabolism, estrogen plus progestin hormone therapy use, and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.08
Abnormal pulmonary vascular responses in patients registered with a systemic autoimmunity database: Pulmonary Hypertension Assessment and Screening Evaluation using stress echocardiography (PHASE-I). Eur J Echocardiogr (2006) 1.08
Selective estrogen receptor-alpha and estrogen receptor-beta agonists rapidly decrease pulmonary artery vasoconstriction by a nitric oxide-dependent mechanism. Am J Physiol Regul Integr Comp Physiol (2008) 1.04
Cardiopulmonary responses of male and female swine to simulated high altitude. J Appl Physiol (1973) 1.00
Genetic polymorphisms in CYP1B1, GSTA1, NQO1 and NAT2 and the risk of lung cancer. Cancer Lett (2005) 0.99
Gene transfer of endothelial nitric oxide synthase to the lung of the mouse in vivo. Effect on agonist-induced and flow-mediated vascular responses. Circ Res (1999) 0.97
PPARgamma and the pathobiology of pulmonary arterial hypertension. Adv Exp Med Biol (2010) 0.93
CYP1B1 expression in human lung. Drug Metab Dispos (2001) 0.92
Hormone replacement therapy may prevent the development of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Scand J Rheumatol (2007) 0.92
Estrogen exposure, obesity and thyroid disease in women with severe pulmonary hypertension. Eur J Med Res (2009) 0.91
G-protein-coupled receptor 30 mediates estrogen's nongenomic effects after hemorrhagic shock and trauma. Am J Pathol (2007) 0.90
Effects of sex hormones on cardiovascular and hematologic responses to chronic hypoxia in rats. Proc Soc Exp Biol Med (1978) 0.89
The protective role of adiponectin in pulmonary vascular disease. Am J Physiol Lung Cell Mol Physiol (2009) 0.89
2-methoxyestradiol attenuates bleomycin-induced pulmonary hypertension and fibrosis in estrogen-deficient rats. Vascul Pharmacol (2009) 0.88
Hormone replacement therapy: a possible risk factor in carriers of familial primary pulmonary hypertension. Chest (1999) 0.88
2-Ethoxyestradiol is antimitogenic and attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling. Vascul Pharmacol (2008) 0.86
Effect of dehydroepiandrosterone on hypoxic pulmonary vasoconstriction: a Ca(2+)-activated K(+)-channel opener. Am J Physiol (1998) 0.85
Characterization of the vasodilatory action of testosterone in the human pulmonary circulation. Vasc Health Risk Manag (2008) 0.84
Endothelin-1 immunoreactivity and mRNA in the transplanted human heart. Transplantation (1995) 0.81
Reproductive hormones and cardiovascular disease mechanism of action and clinical implications. Obstet Gynecol Clin North Am (2002) 0.80
Hysteroscopic sterilization in women with pulmonary vascular disease. Mayo Clin Proc (2008) 0.80
Intravenous epoprostenol for primary pulmonary hypertension. N Engl J Med (1996) 0.75
Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med (2006) 3.59
Association of the metabolic syndrome with pulmonary venous hypertension. Chest (2009) 2.75
EIF2AK4 mutations in pulmonary capillary hemangiomatosis. Chest (2014) 1.88
PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support. Circ Heart Fail (2008) 1.75
High prevalence of occult pulmonary venous hypertension revealed by fluid challenge in pulmonary hypertension. Circ Heart Fail (2013) 1.70
Unrecognized glucose intolerance is common in pulmonary arterial hypertension. J Heart Lung Transplant (2011) 1.58
Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension. Am J Respir Crit Care Med (2008) 1.38
Cytoskeletal defects in Bmpr2-associated pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol (2011) 1.25
Metabolomic analysis of bone morphogenetic protein receptor type 2 mutations in human pulmonary endothelium reveals widespread metabolic reprogramming. Pulm Circ (2012) 1.19
A potential role for insulin resistance in experimental pulmonary hypertension. Eur Respir J (2012) 1.16
Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension. Nat Genet (2013) 1.11
The Diastolic Pressure Gradient Does Not-and Should Not-Predict Outcomes. JACC Heart Fail (2015) 1.10
Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension. Am J Respir Crit Care Med (2012) 1.09
Oxidative injury is a common consequence of BMPR2 mutations. Pulm Circ (2011) 1.06
ACE2 improves right ventricular function in a pressure overload model. PLoS One (2011) 1.03
Idiopathic and heritable PAH perturb common molecular pathways, correlated with increased MSX1 expression. Pulm Circ (2011) 1.00
BMPR2 expression is suppressed by signaling through the estrogen receptor. Biol Sex Differ (2012) 0.95
Development of pulmonary arterial hypertension in women: interplay of sex hormones and pulmonary vascular disease. Womens Health (Lond Engl) (2010) 0.92
Physical activity limitation as measured by accelerometry in pulmonary arterial hypertension. Chest (2012) 0.92
Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertension. Am J Respir Crit Care Med (2015) 0.91
Right ventricular plasticity and functional imaging. Pulm Circ (2012) 0.87
Shorter survival in familial versus idiopathic pulmonary arterial hypertension is associated with hemodynamic markers of impaired right ventricular function. Pulm Circ (2013) 0.87
Prostanoids but not oral therapies improve right ventricular function in pulmonary arterial hypertension. JACC Heart Fail (2013) 0.87
Safety of sapropterin dihydrochloride (6r-bh4) in patients with pulmonary hypertension. Exp Lung Res (2010) 0.86
An evidence-based knowledgebase of pulmonary arterial hypertension to identify genes and pathways relevant to pathogenesis. Mol Biosyst (2014) 0.84
Hyperoxia synergizes with mutant bone morphogenic protein receptor 2 to cause metabolic stress, oxidant injury, and pulmonary hypertension. Am J Respir Cell Mol Biol (2013) 0.84
Phosphodiesterase-5A (PDE5A) is localized to the endothelial caveolae and modulates NOS3 activity. Cardiovasc Res (2011) 0.83
Effect of acute arteriolar vasodilation on capacitance and resistance in pulmonary arterial hypertension. Chest (2015) 0.82
Hemodynamic improvement of pulmonary arterial hypertension after bariatric surgery: potential role for metabolic regulation. Diabetes Care (2013) 0.80
Hysteroscopic sterilization in women with pulmonary vascular disease. Mayo Clin Proc (2008) 0.80
Combination therapy in pulmonary arterial hypertension. Clin Chest Med (2013) 0.80
Elevation of plasma cell-free hemoglobin in pulmonary arterial hypertension. Chest (2014) 0.80
Left atrial hypertension after repeated catheter ablations for atrial fibrillation. J Am Coll Cardiol (2011) 0.78
Programmatic change: lung disease research in the era of induced pluripotency. Am J Physiol Lung Cell Mol Physiol (2011) 0.77
Metabolic Dysfunction in Pulmonary Arterial Hypertension. Curr Hypertens Rep (2015) 0.76
Predictors of diastolic-to-wedge gradient in patients evaluated for pulmonary hypertension. PLoS One (2013) 0.75
Vasodilator-responsive idiopathic pulmonary arterial hypertension: evidence for a new disease? Ann Intern Med (2015) 0.75
Reproducibility of intracardiac and transpulmonary biomarkers in the evaluation of pulmonary hypertension. Pulm Circ (2013) 0.75
The right ventricle in pulmonary hypertension: from dogma to data. Am J Respir Crit Care Med (2010) 0.75
All in the family. Am J Med (2006) 0.75
Growth by association. Am J Med (2007) 0.75
Diagnosing acute pancreatitis. Am J Med (2005) 0.75
A pressing situation. Am J Med (2005) 0.75